Lidocaine/Magnesium — Competitive Intelligence Brief

Lidocaine/Magnesium (Lidocaine/Magnesium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination. Area: Pain management / Anesthesia.

marketed Local anesthetic combination Voltage-gated sodium channels; NMDA receptor Pain management / Anesthesia Small molecule

Target snapshot

Lidocaine/Magnesium (Lidocaine/Magnesium) — University of Wisconsin, Madison. Lidocaine blocks sodium channels to provide local anesthesia, while magnesium acts as a co-factor to enhance anesthetic efficacy and reduce pain signaling.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lidocaine/Magnesium TARGET	Lidocaine/Magnesium	University of Wisconsin, Madison	marketed	Local anesthetic combination	Voltage-gated sodium channels; NMDA receptor
Bupivacaine plus Lidocaine	Bupivacaine plus Lidocaine	University of Alabama at Birmingham	marketed	Local anesthetic combination	Voltage-gated sodium channels
Synera patch for 12hrs/day	Synera patch for 12hrs/day	International Clinical Research Institute	marketed	Topical local anesthetic combination	Voltage-gated sodium channels
Triamcinolone + Lidocaine	Triamcinolone + Lidocaine	MetroHealth Medical Center	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (triamcinolone); voltage-gated sodium channels (lidocaine)
ketorolac + bupivacaine	ketorolac + bupivacaine	The Hospital for Sick Children	marketed	NSAID + local anesthetic combination	COX-1/COX-2 (ketorolac); voltage-gated sodium channels (bupivacaine)
ropivacaine mixed with dexmedetomidine	ropivacaine mixed with dexmedetomidine	The First Hospital of Qinhuangdao	marketed	Local anesthetic combination with alpha-2 adrenergic agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)
Bupivacaine/epinephrine/dexamethasone	Bupivacaine/epinephrine/dexamethasone	Cedars-Sinai Medical Center	marketed	Local anesthetic combination	Voltage-gated sodium channels (bupivacaine); alpha-1 adrenergic receptors (epinephrine); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination class)

1. University of Belgrade · 2 drugs in this class
2. Cedars-Sinai Medical Center · 1 drug in this class
3. Cutia Therapeutics（Wuxi）Co.,Ltd · 1 drug in this class
4. East Carolina University · 1 drug in this class
5. Galderma R&D · 1 drug in this class
6. Hadassah Medical Organization · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of New Mexico · 1 drug in this class
9. Ain Shams University · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class